Vitrolife

Excellence in reproductive health Today, we support customers worldwide - always with sustainability in mind. We are your committed partner for the IVF journey.

Vitrolife is committed to supporting successful treatment outcomes and has been dedicated to IVF since 1994, when the field was still young. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for fertility clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors. Our vision is to enable people to fulfil the dream of having a healthy baby), and we achieve this by supporting our customers in delivering successful treatment outcomes. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. We can help you maximise success. – Together. All the way. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.

05/11/2025

💡What will the IVF lab look like in five years?

In the podcast Inside Reproductive Health, Dr. Denny Sakkas, Chief Scientific Officer at Boston IVF and head of the scientific advisory board for AutoIVF, is trying to predict and shape that response. Listen to what automation really means for embryologists, and how new technologies could transform lab operations, chain of custody, and patient safety.

Access the full podcast here: 👉 https://ow.ly/FZxm50XncKl

04/11/2025

United in purpose, inspired for the future 💙

We would like to extend our heartfelt gratitude to all our customers and colleagues for making ASRM 2025 a truly unforgettable experience! Your enthusiasm and engagement created an inspiring atmosphere filled with innovation, collaboration, and shared purpose. By collaborating and sharing our knowledge, we can continue to make a real difference in fulfilling the dreams of so many families across the world.

We can't wait to see you again next year! 🤝

28/10/2025

Thank you so much to everyone who visited us at our booth on the first day of ASRM!

We are sincerely grateful for the opportunity to connect with so many forward-thinking professionals who are passionate about advancing the field of reproductive medicine. The enthusiasm and curiosity you brought to our booth inspires us to keep pushing boundaries and innovating solutions that enables people to fulfil their dream of a healthy baby.

We look forward to even more inspiring exchanges and discoveries in the upcoming day - welcome to booth 1935!

27/10/2025

ASRM 2025 - welcome to visit us!

We are all looking forward to connecting with you! Stop by our booth 1935 to explore our latest news and highlights, or participate in a session in our Academy Studio. To ensure you don’t miss any of the exciting activities we have planned, please see the complete schedule of sessions here:

👉 https://ow.ly/qjpG50XioPv

We look forward to seeing you there!

23/10/2025

Vitrolife Group interim report Q3 2025 released today!

"Sales for the third quarter increased by 5% in local currencies excluding discontinued business, 3% growth in local currencies. Total sales amounted to SEK 835 (867) million, significantly impacted by currency effects of -7%. Gross margin amounted to 58.9% (58.6) and EBITDA was SEK 253 (289) million resulting in an EBITDA margin of 30.3% (33.4) also impacted by currency fluctuations. We delivered a strong performance in the quarter despite macroeconomic headwinds and geopolitical challenges."

- Bronwyn Brophy O’Connor, CEO of the Vitrolife Group

Read the report here: https://www.vitrolifegroup.com/en/investor-relations/financial-reports

20/10/2025

Excitement is building as we count down to American Society for Reproductive Medicine - ASRM 2025!🎉

Have you selected the presentations you’d like to attend in our Academy Studio? Our Academy Director, Jaco Terblanche, will be your host throughout the programme. Warm welcome to join us at booth 1935 for insightful live sessions on the latest in reproductive health💡

Read more about our attendance at ASRM 2025 here:

https://lnkd.in/dZiMvKEu

16/10/2025

💡The proven effectiveness of EmbryoGlue

Based on science and advanced research capabilities, we aim to deliver a premium quality portfolio of products and services covering the entire reproductive-health journey.

One of our products is EmbryoGlue, a medium developed exclusively for embryo transfer and is the only existing transfer medium with a proven implantation enhancing effect. The use of EmbryoGlue for embryo transfer can increase the clinical pregnancy rate and live birth rate¹.

We have summarised the strongest clinical evidence of EmbryoGlue which demonstrate its effect and safety.

Download here:👉 https://ow.ly/OAaM50XbJ5C

15/10/2025

Today, on World Pregnancy and Infant Loss Remembrance Day, we take a moment to reflect and pay tribute to all families who have experienced the profound loss of a pregnancy or infant.

At Vitrolife Group, we are united in our vision to enable people to fulfil their dream of having a healthy baby. On this important day, let’s stand together to raise awareness of pregnancy loss, Sudden Infant Death Syndrome (SIDS), and infant loss, while continuing our commitment to improving treatment outcomes for patients💙

09/10/2025

💡Collaboration at its best - another workshop finalised!

At Vitrolife Group, our commitment to advancing reproductive health goes hand-in-hand with collaboration and knowledge sharing. Last week, we had the pleasure of hosting a successful two day workshop, where we explored the entire IVF journey - from oocyte retrieval to embryo transfer and cryopreservation, as well as quality control in the lab.

We are grateful for the enthusiastic participation and inspiring dialogue that took place. It's through such collaboration and the exchange of knowledge that we continue to innovate and support the success of IVF clinics worldwide 🌍

Thank you to everyone who joined us - together we continue to strive for excellence and innovation in reproductive health!

07/10/2025

💡Our Academy Studio Programme is finalised! Join us at American Society for Reproductive Medicine, ASRM 2025, for live presentations on the latest in reproductive health.

If you're attending in person, visit our booth to gain insights from leading IVF experts. They will share their knowledge and experiences live at the Vitrolife Group Academy Studio. Our Academy Director, Jaco Terblanche will be your host throughout the programme.

Read more about our attendance at ASRM 2025 here:
https://lnkd.in/dZiMvKEu

01/10/2025

We are looking forward to seeing you at ASRM 2025 in beautiful Texas!

If you're attending, visit us at booth 1935, where we will be giving many insightful presentations and demonstrations throughout the congress in our Vitrolife Group Academy Studio. Stay tuned for the ASRM Vitrolife Group Academy programme, which will be shared soon!

24/09/2025

🎇 With a strong dedication to science and research that provides evidence-backed solutions, it is no surprise that our team has several accepted abstracts (including two oral presentations!) for this year's American Society for Reproductive Medicine - ASRM Scientific Congress & Expo.

🏅 Congratulations to everyone who contributed and continues to go above and beyond to improve patient outcomes and experience!

Adress

Gustaf Werners Gata 2
Västra Frölunda
42132

Webbplats

https://www.vitrolife.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när Vitrolife postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Vill du placera din praktik längst upp i Klinik-listan i Västra Frölunda?

Dela

Typ

Leverantör av medicinsk utrustning

Together. All the way.

Vitrolife was established in Sweden in 1994 when the field of assisted reproduction was still young. The possibility to help people become parents through assisted reproduction became a reality in the 1960s, following the development of a method for fertilising eggs outside the body. The birth of Louise Brown in 1978 – the first baby born as a result of in vitro fertilisation (IVF) – gave new hope to men and women suffering from infertility. As IVF techniques developed, the importance of individual components on IVF success began to be understood. The founders of Vitrolife realised the value of using culture media with consistent and repeatable performance; the manufacturing and delivering of LOTto-LOT consistency they developed is still significant for Vitrolife today. Through well-executed product development, consistent quality controls and the acquisition of other innovative IVF companies, Vitrolife has grown with the market globally. As a result, Vitrolife provides an unbroken chain of quality products, securing results at every step of IVF treatment. Only Vitrolife can guarantee every link in this chain. Our commitment to increase pregnancy rates has never been more dedicated. Together with equally devoted clinics, we are improving IVF success and fulfilling more couples’ greatest dream. We are very proud to be a part of making this happen.